RHS Financial LLC Buys New Shares in Exelixis, Inc. $EXEL

RHS Financial LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,779 shares of the biotechnology company’s stock, valued at approximately $695,000.

Other large investors have also recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. raised its holdings in Exelixis by 0.5% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after acquiring an additional 281 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in Exelixis by 5.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 298 shares in the last quarter. Cim LLC increased its position in shares of Exelixis by 0.9% in the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after purchasing an additional 305 shares during the last quarter. J.W. Cole Advisors Inc. increased its position in shares of Exelixis by 6.5% in the 4th quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 329 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in shares of Exelixis by 3.8% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 333 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on EXEL. Truist Financial decreased their price objective on shares of Exelixis from $56.00 to $52.00 and set a “hold” rating for the company in a research report on Thursday, August 6th. BMO Capital Markets initiated coverage on Exelixis in a report on Tuesday. They issued a “market perform” rating and a $54.00 target price on the stock. Wells Fargo & Company raised their price target on Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, July 13th. Stifel Nicolaus upped their price objective on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Hold” and an average target price of $50.07.

Insider Activity at Exelixis

In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total value of $2,187,757.85. Following the sale, the executive vice president owned 594,741 shares in the company, valued at $29,945,209.35. This trade represents a 6.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 67,000 shares of company stock worth $3,404,652. Insiders own 2.60% of the company’s stock.

Exelixis Trading Up 1.5%

Shares of NASDAQ:EXEL opened at $53.12 on Wednesday. The firm has a 50 day simple moving average of $54.20 and a 200-day simple moving average of $48.35. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $57.57. The company has a market capitalization of $13.16 billion, a PE ratio of 16.70, a P/E/G ratio of 1.53 and a beta of 0.44.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The firm had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. During the same period last year, the firm posted $0.75 EPS. The company’s revenue was up 10.6% on a year-over-year basis. As a group, equities research analysts predict that Exelixis, Inc. will post 3.18 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.